...
首页> 外文期刊>Cytotechnology >Recent developments in ex vivo platelet production
【24h】

Recent developments in ex vivo platelet production

机译:离体血小板生产的最新进展

获取原文

摘要

The platelet is a component of blood that functions to initiate blood clotting. Abnormal platelet count and function can lead to a life-threatening condition caused by excessive bleeding. At present, platelet supply for transfusion can be obtained only from platelet donation. However, platelets cannot be stored for longer than 7?days, meaning that routine isolation is required to maintain platelet supply for transfusion. To mitigate for potential platelet shortages, several strategies have been proposed to generate platelets ex vivo. By employing both of natural and artificial approaches, several researchers have successfully generated biomaterials with characteristics similar to human-derived platelets. Their reports indicated that the biomaterials could mimic the aggregation of human-isolated platelets, further suggesting the possibility to substitute or complement human-isolated platelets. The current review summarizes the progress in ex vivo platelet production and gives a prospect for the possible approaches to achieving a feasible platelet factory, based on the Good Manufacturing Practice standards.
机译:血小板是血液的一部分,起着血液凝结的作用。血小板计数和功能异常会导致过度出血而危及生命。目前,用于输血的血小板供应只能通过捐献血小板来获得。但是,血小板的保存时间不能超过7天,这意味着需要常规隔离以保持血小板供应以进行输血。为了减轻潜在的血小板短缺,已经提出了几种策略来离体产生血小板。通过采用自然和人工方法,几位研究人员成功地制造出了具有与人类血小板相似的特性的生物材料。他们的报告表明,生物材料可以模拟人分离的血小板的聚集,进一步暗示了替代或补充人分离的血小板的可能性。本篇综述总结了离体血小板生产的进展,并根据《药品生产质量管理规范》为实现可行的血小板工厂提供了可能的方法前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号